Experimental vaccine combo for rare adrenal cancers shows early promise but trial halted
NCT ID NCT04187404
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tested a new therapeutic vaccine (EO2401) combined with the immunotherapy drug nivolumab in 70 people with advanced adrenocortical carcinoma or malignant pheochromocytoma/paraganglioma. The goal was to see if the combination is safe and can shrink tumors or slow cancer growth. However, the study was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EO2401 (therapeutic vaccine) and nivolumab (immunotherapy)
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced adrenal cancers that are hard to treat.
What could go wrong
The trial was terminated early, so results are limited. It is a small, early-phase study, and the vaccine may not work or may cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PHEOCHROMOCYTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Amsterdam UMC, location VUmc
Amsterdam, 1081, Netherlands
-
Assistance Publique - Hôpitaux de Marseille - Hôpital Nord
Marseille, 13915, France
-
Azienda Ospedaliera Spedali Civili
Brescia, 25121, Italy
-
Centre Léon Bérard
Lyon, 69008, France
-
Chu Lille
Lille, 59037, France
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Institut Gustave Roussy
Villejuif, 94800, France
-
Karolinska University Hospital
Stockholm, 17176, Sweden
-
Lmu Klinikum
München, Germany
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Rigshospitalet
Copenhagen, 2100, Denmark
-
Universitätsklinikum Würzburg
Würzburg, 97080, Germany